ERBB2 and breast carcinoma: More than 90% of patients with breast cancer are diagnosed at an early stage (eBC), of whom approximately 70% have hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) tumors [1].